Physician profile
Judi Knowles
NPI 1346217122
$7,468.70
in general payments reported to CMS, 2019-2025
30 companies · $29.29 in 2025
The $29.29 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $1,101 · 2021: $1,142 · 2022: $2,085 · 2023: $1,254 · 2024: $815 · 2025: $29.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.86 | 2021-2024 | |
| Allergan, INC. | $648.98 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $632.29 | 2019-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $575.50 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $499.49 | 2019-2024 | Fanapt, Hetlioz |
| Corium, LLC | $438.65 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $382.31 | 2019-2020 | |
| Lundbeck LLC | $366.30 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $301.10 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $298.26 | 2019-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $274.52 | 2019-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $236.93 | 2019-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $233.74 | 2019-2024 | Uzedy, Austedo |
| Adlon Therapeutics L.P. | $207.39 | 2020-2021 | |
| Alkermes, INC. | $192.00 | 2021-2023 | Aristada, Lybalvi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.96 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $125.00 | 2022 | |
| Axsome Therapeutics, INC. | $102.70 | 2023-2024 | Auvelity |
| Tris Pharma INC | $100.85 | 2019-2023 | Dyanavel Xr |
| Neos Therapeutics, Lp | $88.68 | 2021 | |
| Harmony Biosciences LLC | $75.40 | 2024 | |
| Eisai INC. | $72.19 | 2020 | |
| Noven Therapeutics, LLC | $36.11 | 2023 | Xelstrym |
| Shire North American Group INC | $32.62 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $17.65 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.56 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.69 | 2019 | |
| Almatica Pharma LLC | $13.71 | 2022 | |
| Aytu Biopharma, INC. | $13.27 | 2021 | |
| Bausch Health US, LLC | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judi Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.